These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
123 related articles for article (PubMed ID: 22030845)
1. Rofecoxib and clinically significant gastrointestinal events. Bombardier C; Laine L; Day R; Hawkey CJ; Hochberg MC; Schnitzer TJ Am J Med Sci; 2011 Nov; 342(5):438-9. PubMed ID: 22030845 [No Abstract] [Full Text] [Related]
2. Rofecoxib and clinically significant upper and lower gastrointestinal events revisited based on documents from recent litigation. Graham DY; Jewell NP; Chan FK Am J Med Sci; 2011 Nov; 342(5):356-64. PubMed ID: 21986300 [TBL] [Abstract][Full Text] [Related]
3. The NSAID roller coaster: more about rofecoxib. Aronson JK Br J Clin Pharmacol; 2006 Sep; 62(3):257-9. PubMed ID: 16934039 [No Abstract] [Full Text] [Related]
4. Co-administration of rofecoxib and tramadol results in additive or sub-additive interaction during arthritic nociception in rat. García-Hernández L; Déciga-Campos M; Guevara-López U; López-Muñoz FJ Pharmacol Biochem Behav; 2007; 87(3):331-40. PubMed ID: 17570478 [TBL] [Abstract][Full Text] [Related]
5. Reply to the Vioxx debacle. Knudsen JF; Sokol GH Am J Med; 2006 Jan; 119(1):93-4. PubMed ID: 16431207 [No Abstract] [Full Text] [Related]
6. [Innovation of anti-inflammatory drugs--inhibition of cyclooxygenases]. Guo ZR Yao Xue Xue Bao; 2005 Nov; 40(11):967-9. PubMed ID: 16499077 [No Abstract] [Full Text] [Related]
7. Marked interindividual variability in the response to selective inhibitors of cyclooxygenase-2. Fries S; Grosser T; Price TS; Lawson JA; Kapoor S; DeMarco S; Pletcher MT; Wiltshire T; FitzGerald GA Gastroenterology; 2006 Jan; 130(1):55-64. PubMed ID: 16401468 [TBL] [Abstract][Full Text] [Related]
8. Lapses at the new England journal of medicine. Smith R J R Soc Med; 2006 Aug; 99(8):380-2. PubMed ID: 16893926 [No Abstract] [Full Text] [Related]
10. Seeds of doubt--ADVANTAGE no one. Jackson G Int J Clin Pract; 2008 Nov; 62(11):1637. PubMed ID: 19143848 [No Abstract] [Full Text] [Related]
11. Adverse cardiovascular effects of rofecoxib. Nissen SE N Engl J Med; 2006 Jul; 355(2):203-4; author reply 203-5. PubMed ID: 16801355 [No Abstract] [Full Text] [Related]
12. Adverse cardiovascular effects of rofecoxib. Furberg CD N Engl J Med; 2006 Jul; 355(2):204; author reply 204-5. PubMed ID: 16838442 [No Abstract] [Full Text] [Related]
13. Vioxx should be allowed back on the market advises expert panel. Sibbald B CMAJ; 2006 Aug; 175(3):234. PubMed ID: 16880435 [No Abstract] [Full Text] [Related]
14. Cerebrovascular events after discontinuation of rofecoxib treatment. Andersohn F Cardiovasc Drugs Ther; 2007 Apr; 21(2):77-9. PubMed ID: 17404824 [No Abstract] [Full Text] [Related]
15. Withdrawal of rofecoxib - a wake up call for drug safety. Mishra P; Palaian S Kathmandu Univ Med J (KUMJ); 2004; 2(4):360. PubMed ID: 16388250 [No Abstract] [Full Text] [Related]
16. [Rofecoxib increases myocardial infarction risk in seniors]. Wasielewski S Med Monatsschr Pharm; 2005 Nov; 28(11):416-7. PubMed ID: 16309032 [No Abstract] [Full Text] [Related]
17. 94% of patients suing Merck over rofecoxib agree to company's offer. Charatan F BMJ; 2008 Mar; 336(7644):580-1. PubMed ID: 18340064 [No Abstract] [Full Text] [Related]
18. Risk of upper gastrointestinal complications associated with cyclooxygenase-2 selective and nonselective nonsteroidal antiinflammatory drugs. Castellsague J; Holick CN; Hoffman CC; Gimeno V; Stang MR; Perez-Gutthann S Pharmacotherapy; 2009 Dec; 29(12):1397-407. PubMed ID: 19947799 [TBL] [Abstract][Full Text] [Related]